Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up

Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up

Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to...

Full description

Bibliographic Details
Main Authors: Mehrzad Mirzania, Sedigheh Khalili, Akbar Hasanpoor, Ahmad Reza Shamshiri
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2014-06-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Amegakaryocytic thrombocytopenia
Anti-CD20 antibody
Platelet
Online Access:https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/420
id doaj-7e059191e5ce466688c99486a4ba69ab
record_format Article
spelling doaj-7e059191e5ce466688c99486a4ba69ab2020-11-25T04:06:50ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072014-06-0182406Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow upMehrzad Mirzania0Sedigheh Khalili1Akbar Hasanpoor2Ahmad Reza Shamshiri3Imam Khomini Hospital Complex, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.Arak University of Medical Sciences, Arak, Iran.Arak University of Medical Sciences, Arak, Iran.Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/420Amegakaryocytic thrombocytopeniaAnti-CD20 antibodyPlatelet
collection DOAJ
language English
format Article
sources DOAJ
author Mehrzad Mirzania
Sedigheh Khalili
Akbar Hasanpoor
Ahmad Reza Shamshiri
spellingShingle Mehrzad Mirzania
Sedigheh Khalili
Akbar Hasanpoor
Ahmad Reza Shamshiri
Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
International Journal of Hematology-Oncology and Stem Cell Research
Amegakaryocytic thrombocytopenia
Anti-CD20 antibody
Platelet
author_facet Mehrzad Mirzania
Sedigheh Khalili
Akbar Hasanpoor
Ahmad Reza Shamshiri
author_sort Mehrzad Mirzania
title Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_short Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_full Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_fullStr Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_full_unstemmed Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up
title_sort anti-cd20 antibody is effective in the patient with refractory amegakaryocytic thrombocytopenia, 25 months follow up
publisher Tehran University of Medical Sciences
series International Journal of Hematology-Oncology and Stem Cell Research
issn 2008-2207
publishDate 2014-06-01
description Amegakaryocytic thrombocytopenia (AMT) is a rare cause of acquired thrombocytopenia. The pathogenesis and treatment of AMT is not clearly known. Here we demonstrate a 50-year-old man presented with the clinical manifestations of severe thrombocytopenia (7000 platelets/µl) with a marked decrease to absent of megakaryocytes in the bone marrow. The patient did not respond to intravenous immunoglobulin, cyclosporine or high dose prednisone. After the treatment with anti-CD20 antibody (Rituximab), the patient's clinical symptoms and platelet counts improved.
topic Amegakaryocytic thrombocytopenia
Anti-CD20 antibody
Platelet
url https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/420
work_keys_str_mv AT mehrzadmirzania anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT sedighehkhalili anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT akbarhasanpoor anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
AT ahmadrezashamshiri anticd20antibodyiseffectiveinthepatientwithrefractoryamegakaryocyticthrombocytopenia25monthsfollowup
_version_ 1724430527678644224

Similar Items